AUTO-T
Live / Applied — First extension granted (statement of use) (as of 02 Mar 2026)
What this means for you
Not registered yet, but its 25 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98667079
- Mark type
- Stylized text
- Filed
- 25 Jul 2024
- Published for opposition
- 15 Jul 2025
- Attorney of record
- Susan M. Natland
Goods and services
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals, biological preparations, chemical preparations, and reagents for others; biomanufacturing for others, namely, manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; consulting services in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; custom processing and manufacture of vectors, cells and proteins for use in the field of biotechnology; providing technical information about biomanufacturing and manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins
- Class 042 — Scientific and technological services: Research and development, and consulting services related thereto in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; genetic engineering services; biotechnology research and development; scientific, pharmaceutical, and medical research services relating to biological treatment and bioproduction; design and development of technology platforms, namely, biomanufacturing relating to biological treatment for use in the manufacture of pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; provision of information relating to research and development of biopharmaceuticals that are manufactured using biological treatment and bioproduction platforms; development of new technology for others in the field of biotechnology, biomanufacturing, and pharmaceuticals; new product design services; biotechnology design services in the nature of development of new technology for others in the field of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; design and development of biomanufacturing platforms for others, namely, product development for manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process
Owner
- NATIONAL RESILIENCE, LLC, BLUE ASH, OH, US
- National Resilience, Inc., San Diego, CA, US
- National Resilience, Inc., San Diego, CA, US
Prosecution history
- 03 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Mar 2026 — SOU EXTENSION 1 GRANTED
- 02 Mar 2026 — SOU EXTENSION 1 FILED
- 02 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 11 Feb 2026 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 11 Feb 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 11 Feb 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 11 Feb 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 11 Feb 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 09 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Jul 2025 — PUBLISHED FOR OPPOSITION
- 09 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Jun 2025 — EXAMINER'S AMENDMENT ENTERED